Investigating BCG resistance in bladder cancer to find new treatment options
Official title: Multi-scale analysis of Bacillus Calmette-Guérin (BCG) resistant tumor micro-environment in non-muscle invasive bladder cancer to identify novel therapeutic axis
Funded at Icahn School of Medicine at Mount Sinai · NIH-11108450 · Data updated 2026-11-12
This study is looking at why some people with non-muscle invasive bladder cancer don’t respond to the usual treatment with BCG, by examining their tumor samples to find clues that could help improve future treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 17, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $684,877 |
| NIH project number | 1R01CA301050-01 |
| Project ID | NIH-11108450 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with high-risk non-muscle invasive bladder cancer who are undergoing BCG treatment.
✕Less likely to help
Patients with muscle-invasive bladder cancer or those who are not receiving BCG treatment may not benefit from this research.
What this research studies
This research focuses on non-muscle invasive bladder cancer (NMIBC), which is a common type of bladder cancer. It aims to understand why some patients do not respond to the standard treatment with Bacillus Calmette-Guérin (BCG) by analyzing the tumor microenvironment before and after treatment. By using advanced techniques like single-cell and spatial sequencing, the study will create a detailed molecular map of the tumor environment to identify potential new therapeutic targets. Patients' tumor samples will be collected to explore the differences between those who respond to BCG and those who do not.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies for patients with BCG-resistant bladder cancer.
How similar studies have gone: Previous research has shown promise in understanding tumor microenvironments and their role in treatment resistance, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Song, Won-Min — Icahn School of Medicine at Mount Sinai
- Study coordinator: Song, Won-Min
Related research
Other NIH-funded projects on the same topics.
-
Nrf2 in T cells and how it could boost immune power against bladder cancer
A small grant will explore how a T-cell protein called Nrf2 affects muscle-invasive bladder cancer and whether targeting it could help patients respond better to immune therapies.
-
Repurposing spironolactone to treat bladder cancer inside the bladder
Aims to repurpose spironolactone as an intravesical treatment for non-muscle invasive bladder cancer to help prevent recurrence and progression.
-
Body fats and immune signals shaping bladder cancer outlook
This study will look at how body composition and immune/inflammatory states at diagnosis relate to the outlook for people with non-muscle-invasive bladder cancer.
-
Novel combination immunotherapy for non–muscle-invasive bladder cancer
Researchers are testing a new combination approach using a special anti-CD40 antibody with existing bladder cancer therapies to help patients whose NMIBC did not respond to standard BCG treatment.
-
Why some bladder cancers don't respond to BCG treatment
This project will use detailed tissue and genetic tests to look for what makes some non-muscle invasive bladder cancers resist BCG so better treatments can be found for people who don't respond.
-
Salt-based nanomedicine to treat bladder cancer that doesn’t respond to standard BCG therapy
A patient-focused overview of a new salt-based nanoparticle therapy designed to target non-muscle invasive bladder cancer that is resistant to BCG treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.